- Home
- VSTD vs NERV Comparison
VSTD vs NERV Comparison
Compare VSTD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTD
- NERV
- Stock Information
- Founded
- VSTD 2016
- NERV 2007
- Country
- VSTD United States
- NERV United States
- Employees
- VSTD N/A
- NERV N/A
- Industry
- VSTD Restaurants
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- VSTD Consumer Discretionary
- NERV Health Care
- Exchange
- VSTD Nasdaq
- NERV Nasdaq
- Market Cap
- VSTD 17.9M
- NERV 14.6M
- IPO Year
- VSTD 2022
- NERV 2014
- Fundamental
- Price
- VSTD $0.57
- NERV $4.32
- Analyst Decision
- VSTD
- NERV Hold
- Analyst Count
- VSTD 0
- NERV 1
- Target Price
- VSTD N/A
- NERV $4.00
- AVG Volume (30 Days)
- VSTD 541.4K
- NERV 8.7M
- Earning Date
- VSTD 11-14-2025
- NERV 11-05-2025
- Dividend Yield
- VSTD N/A
- NERV N/A
- EPS Growth
- VSTD N/A
- NERV N/A
- EPS
- VSTD N/A
- NERV N/A
- Revenue
- VSTD $13,902,861.00
- NERV N/A
- Revenue This Year
- VSTD N/A
- NERV N/A
- Revenue Next Year
- VSTD N/A
- NERV N/A
- P/E Ratio
- VSTD N/A
- NERV N/A
- Revenue Growth
- VSTD 30.39
- NERV N/A
- 52 Week Low
- VSTD $0.40
- NERV $1.15
- 52 Week High
- VSTD $5.63
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- VSTD N/A
- NERV 59.26
- Support Level
- VSTD N/A
- NERV $3.75
- Resistance Level
- VSTD N/A
- NERV $4.20
- Average True Range (ATR)
- VSTD 0.00
- NERV 0.39
- MACD
- VSTD 0.00
- NERV -0.05
- Stochastic Oscillator
- VSTD 0.00
- NERV 63.85
About VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.